专利检索 ap:("SMITHKLINE BEECHAM PHARMA GmbH" OR "SmithKline Beecham (Australia) Pty Ltd" OR "SMITHKLINE BEECHAM PLC") AND inv:"LICHTENTHALER, Stefan,University of Heidelberg" 第 1 页

1.

发明公开
HUMAN APP OR A4CT SEQUENCES ENCODING THE MUTATION I45F 失效
标题翻译： FOR I45F突变编码人或APP A4CT序列

公开(公告)号：EP1027433A1

公开(公告)日：2000-08-16

申请号：EP98932168.2

申请日：1998-06-09

申请人： SMITHKLINE BEECHAM PHARMA GmbH , SmithKline Beecham (Australia) Pty Ltd , SMITHKLINE BEECHAM PLC

发明人： LICHTENTHALER, Stefan,University of Heidelberg , BEYREUTHER, Konrad,University of Heidelberg , MASTERS, Colin, Louis , BROWN, Frank,SmithKline Beecham Pharmaceuticals , ALLSOP, David,SmithKline Beecham Pharmaceuticals

IPC分类号： C12N15/12 , C12N15/00 , C07K14/47 , A01K67/027 , C12N5/10

CPC分类号： C07K14/4711 , A01K2217/05

摘要： Constructs comprising a human APP or A4CT DNA sequence encoding mutations which lead to a higher ratio of βA41-42/βA41-40 than wild type and their use in the production of transgenic animals developing amyloid plaques as a model of Alzheimer's disease.